Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Actavis Says FDA Accepts NDA For Progestin-only Contraceptive Patch

RELATED NEWS
Trade ACT now with 

Specialty pharmaceutical company Actavis, Inc. (ACT) Monday said the U.S. Food and Drug Administration has accepted for filing its New Drug Application for a progestin-only transdermal contraceptive patch, Norethindrone Transdermal Delivery System, for use by women to prevent pregnancy.

The acceptance of the NDA for filing means FDA has determined that the application is sufficiently complete to permit a substantive review. Under the Prescription Drug User Fee Act, the FDA's goal under standard review is to review and act on the NDA by December 27.

Actavis' progestin-only patch is designed to provide continuous delivery of norethindrone to the systemic circulation during a once-weekly, seven-day dosing regimen.

Actavis said that once-weekly dosing with the patch may improve compliance and convenience in progestin-only contraceptive users, as well as provide more consistent average plasma norethindrone levels than oral progestin-only products.

The NDA includes data from a 12-month, multicenter, open-label clinical trial conducted in the U.S. Actavis submitted the NDA to the FDA on February 26.

The stock is down 2.5 percent in pre-market activity at $117.

Click here to receive FREE breaking news email alerts for Actavis Plc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Suggesting moderate growth in the short-term, the Conference Board released a report on Thursday showing that its index of leading U.S. economic indicators rose by more than economists had anticipated in the month of September. Stocks have moved sharply higher in early trading on Thursday after turning lower over the course of the previous session. The major averages have climbed firmly into positive territory, more than offsetting yesterday's steep losses. Eurozone's consumer confidence improved unexpectedly in October after weakening in the previous four months, preliminary data from the European Commission showed Thursday. The flash consumer confidence indicator rose to -11.1 from a seven-month low of -11.4 in September. Economists had forecast a...
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.